On May 12, the inaugural Hong Kong Embodied AI Industry Summit, co-initiated by the Hong Kong Federation of Overseas Chinese Associations and AgileX Robotics, opened in Hong Kong. John Lee Ka-chiu, Chief Executive of the Hong Kong Special Administrative Region; Frederick Ma Si-hang, Chairman of the Hong Kong Trade Development Council; Cheng Cheung Ling, President of Chia Tai Pharmaceutical Group and President of the Hong Kong Federation of Overseas Chinese Associations, attended the event and delivered speeches.

On the morning of May 11, the 6th Asia Summit on Global Health (ASGH), co-hosted by the HKSAR Government and the Hong Kong Trade Development Council, opened at the Hong Kong Convention and Exhibition Centre.

On May 11, Sino Biopharm (1177.HK) officially announced that its core enterprise, Chia Tai Tianqing, has entered into an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the marketing process of the first-in-class (FIC) new drug Bepirovirsen in China. Earlier this year, a marketing application for Bepirovirsen was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was included in the priority review list.

On May 6, the website of the National Medical Products Administration (NMPA) showed that the second indication for Culmerciclib Capsules (Saitanxin®), independently developed by Chia Tai Tianqing, the core enterprise of Sino Biopharm (1177.HK), has been approved for marketing.